

FASTER — HIGHER — STRONGER:
the global race for a COVID-19 therapy

Therapeutic Numbers

3,042

on-going clinical trials are registered in the US and EU combined.

1,259

studies are designated as phase I, II, or III-(I,II,III)
If phase 2/3 trial, it was counted as phase 3; phase 1/2 counted as phase 2.

PHASE I	17.9%
PHASE II	48.1%
PHASE III	34.0%




US	Both	EUR
90.0% 2,737	6.5% 198	3.5% 107

Total Number of pharma companies studying COVID treatments

47

US 33

EUR 14



These treatments are being studied to treat **COVID-19 stages**



16.9%
10/59
at time of diagnosis



69.5%
41/59
when hospitalized



13.6%
8/59
when ventilators are used

70% 41/59
are existing treatments for other indications

27% 11/41
of these are available as generic

With **70%** being existing products and of these **27%** generic, not only will treatments be available soon, they will be affordable and safety has been extensively assessed with long term clinical use.

References:

- EU Clinical Trials Register. (2020). Retrieved August 18, 2020, from <https://www.clinicaltrialsregister.eu/>
- NIH US National Library of Medicine ClinicalTrials.gov. (2020). Retrieved August 18, 2020, from <https://clinicaltrials.gov/>
- Orphanet. (2020). Retrieved August 18, 2020, from <https://www.orpha.net/consor4.01/www/cgi-bin/index.php?lng=EN>